1 September 2022

Physiomics plc

("Physiomics") or ("the Company")

Physiomics appoints new Independent Non-Executive Director

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that Mr Shalabh Kumar has joined the Company's board as an Independent Non-Executive Director with immediate effect.

Mr Shalabh Kumar is a proven business executive with over 30 years of experience within the life sciences consulting and services industry. Shalabh co-founded, and subsequently was the Chief Executive Officer of Kinapse, a life sciences consulting and outsourcing service provider, which was later acquired by Syneos Health® (Nasdaq: SYNH) after growing to employ over 600 people across UK, India and US. Prior to that, he worked for Accenture, Gillette (Procter & Gamble) and Unilever. More recently, Shalabh has been working as an independent strategy consultant and angel investor in the life sciences industry, working with biopharmaceutical companies, life sciences services and technology companies and private equity firms. Mr Kumar's recent roles include Chairman of the Board of Clustermarket Ltd, a lab software start-up; independent strategy consultant to the life sciences R&D group of Accenture plc (NYSE: ACN); and Global Head of Services at Navitas Life Sciences, a technology-backed life sciences contract research organisation.

Dr Jim Millen, CEO, commented: "On behalf of the board of Physiomics, we are delighted that Shalabh has agreed to join the Company as an Independent Non-Executive Director. Shalabh has impressive business acumen within the life sciences sector and has overseen the successful implementation of growth strategies at a number of companies. We look forward to working alongside Shalabh in the future and welcome the insight he can provide to Physiomics."

Further information on Shalabh Kumar's appointment:

The following details in relation to the appointment of Mr Shalabh Kumar are disclosed in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules:

Shalabh Kumar (aged 55) has held the following directorships in the past five years.

There is no further information to be disclosed in relation to Shalabh Kumar's appointment pursuant to AIM Rule 17 or Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies.

Enquiries:

Physiomics plc                                                  

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.